Results 21 to 30 of about 9,015 (261)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review

BMJ Paediatrics Open, 2021
In Italy, reimbursement restrictions regarding palivizumab prophylaxis approved in 2016 have been revoked in 2017, restoring use in infants with Gestational Age (GA) >29 weeks.
Marina Davoli, Federico Marchetti, Antonio Addis, Valeria Belleudi, Marco Finocchietti   +4 more
doaj   +1 more source

Does Prophylaxis Against Respiratory Syncytial Virus Infection Affect the Weight Percentiles of Infants with Hemodynamically Significant Congenital Heart Disease?

Journal of Behçet Uz Children's Hospital, 2021
Objective: The risk of severe respiratory syncytial virus (RSV) infection with significant morbidity and mortality is greatest in patients with hemodynamically significant congenital heart disease (hs-CHD). The humanized monoclonal antibody, palivizumab,
Ali Orgun, İbrahim İlker Çetin, Hazım Alper Gürsu   +2 more
doaj   +1 more source

Partial Degradation of Recombinant Antibody Functional Activity During Infant Gastrointestinal Digestion: Implications for Oral Antibody Supplementation

Frontiers in Nutrition, 2020
Oral administration of engineered immunoglobulins has the potential to prevent enteric pathogen-induced diarrhea in infants. To prevent infection, these antibodies need to survive functionally intact in the proteolytic environment of the gastrointestinal
Baidya Nath P. Sah, Jiraporn Lueangsakulthai, Bum Jin Kim, Benjamin R. Hauser, Yeonhee Woo, Amy Olyaei, Molly Aloia, Ann O'Connor, Brian Scottoline, Manoj K. Pastey, David C. Dallas   +10 more
doaj   +1 more source

Linking pharmacy dispensing data to other administrative health datasets to measure the compliance and effectiveness of RSV immunoprophylaxis

International Journal of Population Data Science, 2018
Introduction Respiratory Syncytial Virus (RSV) causes considerable morbidity in children. RSV vaccines are in development, but the only current preventive measure is immunoprophylaxis with monoclonal antibody, palivizumab.
Hannah Moore, Tobias Strunk, Tasnim Abdalla, Tom Snelling, Peter Richmond, Anthony Keil, Nicholas de Klerk   +6 more
doaj   +1 more source

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

BMC Pediatrics, 2020
Background The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV).
Ruomei Xu, Parveen Fathima, Tobias Strunk, Nicholas de Klerk, Thomas L. Snelling, Peter C. Richmond, Anthony D. Keil, Hannah C. Moore   +7 more
doaj   +1 more source

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children

Drugs in Context, 2015
Background: The peak season of respiratory syncytial virus (RSV) infections in warmer climates may extend beyond the typical five-month RSV season of temperate regions. Additional monthly doses of palivizumab may be necessary in warmer regions to protect
Saleh al-Alaiyan, Paul Pollack, Gerard F Notario   +2 more
doaj   +1 more source

Early respiratory viral infections in infants with cystic fibrosis [PDF]

, 2015
This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
A Peshkin, C Castoriadis, C Hauke, C Lasch, C Mayes, C Mayes, CG Jung, CG Jung, DC Dennett, I Semetsky, I Semetsky, J Blackmore, J Campbell, J Campbell, J Cole, J Conroy, J Conroy, J Day, J Lecoq, J Parini, JC Conroy, JR Searle, JV Wertsch, K Johnstone, K Kristjansson, LA Russell-Chapin, M Currie, M Harding, M Lynch, M Merleau-Ponty, R Leitch, R Leitch, R Leitch, R Segal, RH Hopcke, S Rowland, S Walsh, T Barone, V John-Steiner, V Villate, W James, W Sorrell   +41 more
core   +2 more sources

Initial Palivizumab Dose Administration in Outpatient Clinic After Hospital Discharge [PDF]

, 2018
BACKGROUND:Palivizumab provides passive immunity for respiratory syncytial virus (RSV), but poor adherence compromises protection. A hospital initiative promoted administration of first palivizumab doses at an outpatient clinic immediately after ...
Chen, Yanjun, Chilvers Murphy, Michelle, Jun, Allison, Lee, Tina, Magedman, Grace, Stockton, Winifred   +5 more
core   +1 more source

Respiratory syncytial virus: Clinical and epidemiological pattern in pediatric patients admitted to a children’s hospital between 2000 and 2013 [PDF]

, 2014
INTRODUCTION: Respiratory syncytial virus (RSV) is the major causative organism associated with acute lower respiratory tract infections in children.The objective of this study was to describe the clinical and epidemiological pattern of RSV and identify ...
Bakir, Julia, Castellano, Verónica, Gentile, Ángela, Grobaporto, Marcela, Juárez, María del Valle, Lucion, María Florencia, Mistchenko, Alicia Susana, Romanin, Viviana Sandra, Viegas, Mariana   +8 more
core   +1 more source

Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study

Italian Journal of Pediatrics, 2023
Background In children with congenital heart disease (CHD) respiratory syncytial virus (RSV) infection may have a severe course, with increased risk of morbidity and mortality, requiring hospital admission and intensive care. The aim of the present study
Chiara Ratti, Anna della Greca, Deborah Bertoncelli, Monica Rubini, Bertrand Tchana   +4 more
doaj   +1 more source